These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 36473488)

  • 1. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
    Bowyer AE; Gosselin RC
    Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on Laboratory Diagnostics in Haemophilia A and B.
    Müller J; Miesbach W; Prüller F; Siegemund T; Scholz U; Sachs UJ;
    Hamostaseologie; 2022 Aug; 42(4):248-260. PubMed ID: 35104901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level.
    Baig MA; Swamy KB
    Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
    Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
    J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
    Strijbis VJF; Romano LGR; Cheung KL; Eikenboom J; Liu YP; McCreary AC; Leebeek FWG; Bos MHA
    J Thromb Haemost; 2023 Jun; 21(6):1466-1477. PubMed ID: 36863564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
    Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
    J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents.
    Kershaw G
    Semin Thromb Hemost; 2024 Nov; 50(8):1163-1172. PubMed ID: 38866040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.